Corvus Pharmaceuticals Inc (CRVS)
1.78
-0.07
(-3.78%)
USD |
NASDAQ |
Jul 02, 16:00
1.78
0.00 (0.00%)
After-Hours: 20:00
Corvus Pharmaceuticals Research and Development Expense (TTM): 16.01M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 16.01M |
| December 31, 2023 | 16.53M |
| September 30, 2023 | 16.61M |
| June 30, 2023 | 23.01M |
| March 31, 2023 | 23.96M |
| December 31, 2022 | 24.47M |
| September 30, 2022 | 25.18M |
| June 30, 2022 | 21.80M |
| March 31, 2022 | 25.98M |
| December 31, 2021 | 29.12M |
| September 30, 2021 | 31.52M |
| June 30, 2021 | 31.15M |
| March 31, 2021 | 29.90M |
| December 31, 2020 | 31.83M |
| September 30, 2020 | 33.56M |
| June 30, 2020 | 35.94M |
| March 31, 2020 | 38.72M |
| Date | Value |
|---|---|
| December 31, 2019 | 37.98M |
| September 30, 2019 | 37.45M |
| June 30, 2019 | 36.83M |
| March 31, 2019 | 35.90M |
| December 31, 2018 | 38.59M |
| September 30, 2018 | 39.88M |
| June 30, 2018 | 42.24M |
| March 31, 2018 | 44.91M |
| December 31, 2017 | 46.30M |
| September 30, 2017 | 45.75M |
| June 30, 2017 | 42.72M |
| March 31, 2017 | 37.46M |
| December 31, 2016 | 29.36M |
| September 30, 2016 | 25.13M |
| June 30, 2016 | 19.94M |
| March 31, 2016 | 14.82M |
| December 31, 2015 | 11.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
16.01M
Minimum
Mar 2024
38.72M
Maximum
Mar 2020
27.93M
Average
29.12M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Enanta Pharmaceuticals Inc | 151.11M |
| Nanoviricides Inc | 7.168M |
| Amphastar Pharmaceuticals Inc | 70.97M |
| FibroGen Inc | 246.77M |
| Flora Growth Corp | 0.093M |